WASHINGTON (Reuters) – A whistleblower who says he was removed as director of a government research office because he raised concerns about coronavirus preparedness will testify before a U.S. House of Representatives panel on Thursday.

The House Committee on Energy and Commerce’s health subcommittee will hear from Rick Bright, who until last month served as director of the Biomedical Advanced Research and Development Authority, or BARDA, which is responsible for developing drugs to fight the coronavirus outbreak.

“Science – not politics or cronyism – must lead the way to combat this deadly virus,” Bright will testify, according to written remarks made public on Wednesday.

Bright said he wanted his testimony to be “forward looking,” adding that the U.S. faces “grave risks” if it eases restrictions too quickly and fails to develop a national coordinated response.

He is to testify two days after leading U.S. infectious disease expert Dr. Anthony Fauci warned a Senate committee that a premature lifting of lockdowns could lead to additional outbreaks of the deadly coronavirus. President Donald Trump blocked Fauci from testifying to the Democratic-controlled House.

In a whistleblower complaint filed with a government watchdog last week, Bright said that he warned about the virus in January and was met with hostility from leaders of the U.S. Department of Health and Human Services, who oversee BARDA.

Bright, who was reassigned to a new government job last month, said he was ousted from BARDA because he resisted efforts to push hydroxychloroquine and the related chloroquine as cures for COVID-19, the respiratory illness caused by the coronavirus.

Bright said in the statement last month that the U.S. government has promoted the medicines as a “panacea” even though they “clearly lack scientific merit.”

HHS spokeswoman Caitlin Oakley has disputed Bright’s account, saying in a statement on Tuesday that he was transferred to a job where he was entrusted to spend around $1 billion to develop diagnostic testing.

“We are deeply disappointed that he has not shown up to work on behalf of the American people and lead on this critical endeavor,” Oakley said.

The House subcommittee will also hear on Thursday from Mike Bowen, co-owner of Prestige Ameritech, the largest U.S. surgical mask producer.

Bowen warned in January that the United States would run out of medical-grade face masks if it did not ramp up production, according to emails included in Bright’s whistleblower complaint.

Reporting by Jan Wolfe; Editing by Scott Malone and Cynthia Osterman

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Johnson and Cummings have revealed their flawed view of what strong leadership is

We must shield the vulnerable. This is what most of us have understood for the past 10 weeks. Most families have been split apart, often in dire circumstances. For adults and parents of children with compromised immune systems, this remains…

Who is Lindsey Graham? 5 things to know about the SC senator

Sen. Lindsey Graham, R-S.C., praises Trump on economy, hits Biden on oil industry comments. Sen. Lindsey Graham, R-S.C., is locked in a fierce battle to defend his Senate seat, which his party has held for nearly two decades, after his opponent,…

New Hampshire living rooms essential stop on the campaign trail

CONCORD, N.H. (Reuters) – The road to victory in New Hampshire’s critical Democratic primary on Tuesday may run through the living rooms of people like Gerri and Ron King. On a recent weekend, the couple baked berry souffles and roasted…

Congressional investigation finds over $1 billion in PPP fraud

Over $1 billion in emergency coronavirus aid relief went to companies who “double dipped” and received multiple Paycheck Protection Program loans, in violation of the program’s rules, according to a preliminary analysis released by the House Select Subcommittee on the…